Skip to main content
SpringerLink
Log in

Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences

  • Chapter
  • First Online:
Molecular Genetics of Endometrial Carcinoma

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 943))

Abstract

Endometrial carcinoma is the most common gynecologic cancer in developed nations, and the annual incidence is projected to increase, secondary to the high prevalence of obesity, a strong endometrial carcinoma risk factor. Although endometrial carcinomas are etiologically, biologically, and clinically diverse, hormonal and metabolic mechanisms are particularly strongly implicated in the pathogenesis of endometrioid carcinoma, the numerically predominant subtype. The centrality of hormonal and metabolic disturbances in the pathogenesis of endometrial carcinoma, combined with its slow development from well-characterized precursors in most cases, offers a substantial opportunity to reduce endometrial carcinoma mortality through early detection, lifestyle modification, and chemoprevention. In this chapter, we review the epidemiology of endometrial carcinoma, emphasizing theories that link risk factors for these tumors to hormonal and metabolic mechanisms. Future translational research opportunities related to prevention are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cook LS, Weiss NS, Doherty JA, et al. Endometrial cancer. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. 2006. p. 1027–43.

    Google Scholar 

  2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Secondary GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013.

    Google Scholar 

  3. Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976;294(23):1259–62. doi:10.1056/NEJM197606032942303.

    CAS  PubMed  Google Scholar 

  4. Surveillance E and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2013 Sub (1973–2011) < Single Ages to 85+, Katrina/Rita Population Adjustment > - Linked To County Attributes - Total U.S., 1969-2012 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch.

  5. American Cancer Society. Cancer facts & figures 2015. Atlanta: American Cancer Society; 2015.

    Google Scholar 

  6. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. doi:10.1158/0008-5472.CAN-14-0155.

    CAS  PubMed  Google Scholar 

  7. Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol. 2014;10(16):2561–8. doi:10.2217/fon.14.192.

    CAS  PubMed  Google Scholar 

  8. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–66. doi:10.1002/cncr.27514.

    PubMed  PubMed Central  Google Scholar 

  9. Duong LM, Wilson RJ, Ajani UA, et al. Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Women’s Health. 2011;20(8):1157–63. doi:10.1089/jwh.2010.2529.

    Google Scholar 

  10. Joinpoint Regression Program, Version 4.1.1 - August 2014 [program].

    Google Scholar 

  11. Siegel RL, Devesa SS, Cokkinides V, et al. State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. Cancer Epidemiol Biomark Prev. 2013;22(1):25–31. doi:10.1158/1055-9965.EPI-12-0991.

    Google Scholar 

  12. Jamison PM, Noone AM, Ries LA, et al. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomark Prev. 2013;22(2):233–41. doi:10.1158/1055-9965.EPI-12-0996.

    Google Scholar 

  13. S. G. O. Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134(2):385–92. doi:10.1016/j.ygyno.2014.05.018.

    Google Scholar 

  14. Surveillance E and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973–2011 varying) - Linked To County Attributes - Total U.S., 1969–2012 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch.

  15. S. G. O. Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393–402. doi:10.1016/j.ygyno.2014.06.003.

    Google Scholar 

  16. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    CAS  PubMed  Google Scholar 

  17. Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.

    Google Scholar 

  18. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129(2):277–84. doi:10.1016/j.ygyno.2013.02.023.

    PubMed  PubMed Central  Google Scholar 

  19. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37(6):874–81. doi:10.1097/PAS.0b013e31827f576a.

    PubMed  Google Scholar 

  20. Liu Y, Patel L, Mills GB, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Journal of the National Cancer Institute 2014;106(9) doi: 10.1093/jnci/dju245

  21. Wang C, Mayer JA, Mazumdar A, et al. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol. 2011;25(9):1527–38. doi:10.1210/me.2011-1037.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Hurtado A, Holmes KA, Ross-Innes CS, et al. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43(1):27–33. doi:10.1038/ng.730.

    CAS  PubMed  Google Scholar 

  23. Kazi AA, Molitoris KH, Koos RD. Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod. 2009;81(2):378–87. doi:10.1095/biolreprod.109.076117.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Bircan S, Ensari A, Ozturk S, et al. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res. 2005;11(1):32–9. http://dx.doi.org/PAOR.2005.11.1.0032.

    CAS  PubMed  Google Scholar 

  25. Wang J, Bao W, Qiu M, et al. Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor alpha. Oncol Rep. 2014;31(3):1225–34. doi:10.3892/or.2014.2982.

    CAS  PubMed  Google Scholar 

  26. Tangen IL, Krakstad C, Halle MK, et al. Switch in FOXA1 status associates with endometrial cancer progression. PLoS One. 2014;9(5):e98069. doi:10.1371/journal.pone.0098069.

    PubMed  PubMed Central  Google Scholar 

  27. Abe Y, Ijichi N, Ikeda K, et al. Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. Cancer Sci. 2012;103(4):806–12. doi:10.1111/j.1349-7006.2012.02201.x.

    CAS  PubMed  Google Scholar 

  28. Sivridis E, Giatromanolaki A, Gatter KC, et al. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002;95(5):1055–63. doi:10.1002/cncr.10774.

    CAS  PubMed  Google Scholar 

  29. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91. doi:10.1038/nrc1408.

    CAS  PubMed  Google Scholar 

  30. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev. 2002;11(12):1531–43.

    CAS  Google Scholar 

  31. The endometrium. 2nd ed. United Kingdom: Informa Healthcare, 2008

    Google Scholar 

  32. Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57(2):205–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108(3):425–32. doi:10.1002/ijc.11529.

    CAS  PubMed  Google Scholar 

  34. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15(2):485–97. doi:10.1677/ERC-07-0064.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev. 2008;17(4):921–9. doi:10.1158/1055-9965.EPI-07-2686.

    CAS  Google Scholar 

  36. Wu X, Subramaniam M, Negron V, et al. Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem. 2012;113(2):711–23. doi:10.1002/jcb.23443.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Walker VR, Korach KS. Estrogen receptor knockout mice as a model for endocrine research. ILAR J. 2004;45(4):455–61.

    CAS  PubMed  Google Scholar 

  38. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11(8):597–608. doi:10.1038/nrc3093.

    CAS  PubMed  Google Scholar 

  39. Hapangama DK, Kamal AM, Bulmer JN. Estrogen receptor beta: the guardian of the endometrium. Hum Reprod Update. 2015;21(2):174–93. doi:10.1093/humupd/dmu053.

    CAS  PubMed  Google Scholar 

  40. Kurita T, Young P, Brody JR, et al. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology. 1998;139(11):4708–13. doi:10.1210/endo.139.11.6317.

    CAS  PubMed  Google Scholar 

  41. Mote PA, Balleine RL, McGowan EM, et al. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum Reprod. 2000;15 Suppl 3:48–56.

    CAS  PubMed  Google Scholar 

  42. Diep CH, Daniel AR, Mauro LJ, et al. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54(2):R31–53. doi:10.1530/JME-14-0252.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Jeon YT, Park IA, Kim YB, et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett. 2006;239(2):198–204. doi:10.1016/j.canlet.2005.08.001.

    CAS  PubMed  Google Scholar 

  44. Sivridis E, Giatromanolaki A, Koukourakis M, et al. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 2001;438(5):470–7.

    CAS  PubMed  Google Scholar 

  45. Chambers JT, MacLusky N, Eisenfield A, et al. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol. 1988;31(1):65–81.

    CAS  PubMed  Google Scholar 

  46. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 2010;11(1):215–20.

    PubMed  Google Scholar 

  47. Gehrig PA, Van Le L, Olatidoye B, et al. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;86(10):2083–9.

    CAS  PubMed  Google Scholar 

  48. Tangen IL, Werner HM, Berg A, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014;50(17):3003–10. doi:10.1016/j.ejca.2014.09.003.

    CAS  PubMed  Google Scholar 

  49. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2007;106(2):325–33. doi:10.1016/j.ygyno.2007.03.042.

    CAS  PubMed  Google Scholar 

  50. Jongen V, Briet J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112(3):537–42. doi:10.1016/j.ygyno.2008.10.032.

    CAS  PubMed  Google Scholar 

  51. Miyamoto T, Watanabe J, Hata H, et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol. 2004;92(3):111–8. doi:10.1016/j.jsbmb.2004.07.007.

    CAS  PubMed  Google Scholar 

  52. Hanekamp EE, Gielen SC, Smid-Koopman E, et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res. 2003;9(11):4190–9.

    CAS  PubMed  Google Scholar 

  53. Arnett-Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001;61(11):4576–82.

    CAS  PubMed  Google Scholar 

  54. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007;43(16):2434–44. doi:10.1016/j.ejca.2007.08.014.

    CAS  PubMed  Google Scholar 

  55. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993;71(4 Suppl):1467–70.

    CAS  PubMed  Google Scholar 

  56. Trovik J, Wik E, Werner HM, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer. 2013;49(16):3431–41. doi:10.1016/j.ejca.2013.06.016.

    CAS  PubMed  Google Scholar 

  57. Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 1998;69(3):220–5. doi:10.1006/gyno.1998.5023.

    CAS  PubMed  Google Scholar 

  58. Steiner E, Eicher O, Sagemuller J, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer. 2003;13(2):197–203.

    CAS  PubMed  Google Scholar 

  59. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130–62. doi:10.1210/er.2012-1043.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Sasaki M, Dharia A, Oh BR, et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 2001;61(1):97–102.

    CAS  PubMed  Google Scholar 

  61. Saito S, Ito K, Nagase S, et al. Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Sci. 2006;97(12):1308–14. doi:10.1111/j.1349-7006.2006.00332.x.

    CAS  PubMed  Google Scholar 

  62. Leslie KK, Thiel KW, Reyes HD, et al. The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int. 2013;2013:479541. doi:10.1155/2013/479541.

    PubMed  PubMed Central  Google Scholar 

  63. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13(8):e353–61. doi:10.1016/S1470-2045(12)70213-9.

    PubMed  Google Scholar 

  64. Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol. 2003;129(4):245–9. doi:10.1007/s00432-003-0427-9.

    CAS  PubMed  Google Scholar 

  65. Rizner TL. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol. 2013;381(1-2):124–39. doi:10.1016/j.mce.2013.07.026.

    CAS  PubMed  Google Scholar 

  66. Hevir N, Sinkovec J, Rizner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol. 2011;331(1):158–67. doi:10.1016/j.mce.2010.09.011.

    CAS  PubMed  Google Scholar 

  67. Pathirage N, Di Nezza LA, Salmonsen LA, et al. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril. 2006;86(2):469–72. doi:10.1016/j.fertnstert.2005.12.057.

    PubMed  Google Scholar 

  68. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192(4):1262–71. doi:10.1016/j.ajog.2005.01.009. discussion 71–3.

    CAS  PubMed  Google Scholar 

  69. Segawa T, Shozu M, Murakami K, et al. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res. 2005;11(6):2188–94. doi:10.1158/1078-0432.CCR-04-1859.

    CAS  PubMed  Google Scholar 

  70. Watanabe K, Sasano H, Harada N, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol. 1995;146(2):491–500.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Sinreih M, Hevir N, Rizner TL. Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer. Chem Biol Interact. 2013;202(1-3):210–7. doi:10.1016/j.cbi.2012.11.012.

    CAS  PubMed  Google Scholar 

  72. Rizner TL, Smuc T, Rupreht R, et al. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol. 2006;248(1-2):126–35. doi:10.1016/j.mce.2005.10.009.

    CAS  PubMed  Google Scholar 

  73. Smuc T, Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009;301(1-2):74–82. doi:10.1016/j.mce.2008.09.019.

    CAS  PubMed  Google Scholar 

  74. Rizner TL, Penning TM. Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids. 2014;79:49–63. doi:10.1016/j.steroids.2013.10.012.

    CAS  PubMed  Google Scholar 

  75. Smuc T, Rupreht R, Sinkovec J, et al. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol. 2006;248(1–2):114–7. doi:10.1016/j.mce.2005.10.013.

    CAS  PubMed  Google Scholar 

  76. Lepine J, Audet-Walsh E, Gregoire J, et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab. 2010;95(6):2689–98. doi:10.1210/jc.2010-2648.

    CAS  PubMed  Google Scholar 

  77. Cornel KM, Kruitwagen RF, Delvoux B, et al. Overexpression of 17beta-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17beta-estradiol. J Clin Endocrinol Metab. 2012;97(4):E591–601. doi:10.1210/jc.2011-2994.

    CAS  PubMed  Google Scholar 

  78. Chan QK, Khoo US, Chan KY, et al. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn. 2005;7(1):8–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Singh MN, Stringfellow HF, Walsh MJ, et al. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology. 2008;249(1):85–90. doi:10.1016/j.tox.2008.04.009.

    CAS  PubMed  Google Scholar 

  80. Ito K, Utsunomiya H, Suzuki T, et al. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol. 2006;248(1-2):136–40. doi:10.1016/j.mce.2005.11.038.

    CAS  PubMed  Google Scholar 

  81. Zakharov V, Lin HK, Azzarello J, et al. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol. 2010;3(6):608–17.

    PubMed  PubMed Central  Google Scholar 

  82. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446–51. doi:10.1038/ng.2823.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Carlson KE, Choi I, Gee A, et al. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry. 1997;36(48):14897–905. doi:10.1021/bi971746l.

    CAS  PubMed  Google Scholar 

  84. Lebeau A, Grob T, Holst F, et al. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol. 2008;216(2):151–7. doi:10.1002/path.2405.

    CAS  PubMed  Google Scholar 

  85. Rahman MT, Nakayama K, Rahman M, et al. ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis. Anticancer Res. 2013;33(9):3775–81.

    PubMed  Google Scholar 

  86. Tan DS, Lambros MB, Marchio C, et al. ESR1 amplification in endometrial carcinomas: hope or hyperbole? J Pathol. 2008;216(3):271–4. doi:10.1002/path.2432.

    CAS  PubMed  Google Scholar 

  87. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095.

    PubMed  Google Scholar 

  88. Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58(12):2500–3.

    CAS  PubMed  Google Scholar 

  89. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58(15):3254–8.

    CAS  PubMed  Google Scholar 

  90. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006;12(20 Pt 1):5932–5. doi:10.1158/1078-0432.CCR-06-1375.

    CAS  PubMed  Google Scholar 

  91. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924–30.

    CAS  PubMed  Google Scholar 

  92. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 2001;61(11):4311–4.

    CAS  PubMed  Google Scholar 

  93. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. doi:10.1158/1078-0432.CCR-11-2283.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Ngeow J, Stanuch K, Mester JL, et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol. 2014;32(17):1818–24. doi:10.1200/JCO.2013.53.6656.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Mutter GL, Monte NM, Neuberg D, et al. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res. 2014;74(10):2796–802. doi:10.1158/0008-5472.CAN-14-0108.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Joshi A, Wang H, Jiang G, et al. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor alpha. Am J Pathol. 2012;180(6):2536–47. doi:10.1016/j.ajpath.2012.03.006.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Fyles A, Wood G, Li M, et al. Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice. Gynecol Oncol. 2008;108(2):395–401. doi:10.1016/j.ygyno.2007.10.033.

    CAS  PubMed  Google Scholar 

  98. Vilgelm A, Lian Z, Wang H, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 2006;66(7):3375–80. doi:10.1158/0008-5472.CAN-05-4019.

    CAS  PubMed  Google Scholar 

  99. Kim HI, Kim TH, Lim JM, et al. Steroid hormone intervenes in the endometrial tumorigenesis of pten ablation. J Cancer Prev. 2013;18(4):313–21.

    PubMed  PubMed Central  Google Scholar 

  100. Saito F, Tashiro H, To Y, et al. Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model. Int J Gynecol Cancer. 2011;21(8):1343–9. doi:10.1097/IGC.0b013e31822d2a8a.

    PubMed  Google Scholar 

  101. Janzen DM, Rosales MA, Paik DY, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res. 2013;73(15):4697–710. doi:10.1158/0008-5472.CAN-13-0930.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Kim TH, Wang J, Lee KY, et al. The synergistic effect of conditional pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol. 2010;2010:139087. doi:10.1155/2010/139087.

    PubMed  Google Scholar 

  103. Aleixandre de Artinano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br J Nutr. 2009;102(9):1246–53. doi:10.1017/S0007114509990729.

    CAS  PubMed  Google Scholar 

  104. Zhang Q, Shen Q, Celestino J, et al. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol. 2009;200(2):186 e1–8. doi:10.1016/j.ajog.2008.08.064.

    Google Scholar 

  105. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293(23):1164–7. doi:10.1056/NEJM197512042932302.

    CAS  PubMed  Google Scholar 

  106. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293(23):1167–70. doi:10.1056/NEJM197512042932303.

    CAS  PubMed  Google Scholar 

  107. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304–13. doi:10.1016/0029-7844(94)00383-O.

    CAS  PubMed  Google Scholar 

  108. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993;81(2):265–71.

    CAS  PubMed  Google Scholar 

  109. Finkle WD, Greenland S, Miettinen OS, et al. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control. 1995;6(2):99–102.

    CAS  PubMed  Google Scholar 

  110. Green PK, Weiss NS, McKnight B, et al. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control. 1996;7(6):575–80.

    CAS  PubMed  Google Scholar 

  111. Hulka BS, Fowler Jr WC, Kaufman DG, et al. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol. 1980;137(1):92–101.

    CAS  PubMed  Google Scholar 

  112. Levi F, La Vecchia C, Gulie C, et al. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer. 1993;29A(10):1445–9.

    CAS  PubMed  Google Scholar 

  113. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294(23):1262–7. doi:10.1056/NEJM197606032942304.

    CAS  PubMed  Google Scholar 

  114. Pettersson B, Adami HO, Persson I, et al. Climacteric symptoms and estrogen replacement therapy in women with endometrial carcinoma. Acta Obstet Gynecol Scand. 1986;65(1):81–7.

    CAS  PubMed  Google Scholar 

  115. Shapiro S, Kaufman DW, Slone D, et al. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med. 1980;303(9):485–9. doi:10.1056/NEJM198008283030903.

    CAS  PubMed  Google Scholar 

  116. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148(3):234–40.

    CAS  PubMed  Google Scholar 

  117. Stavraky KM, Collins JA, Donner A, et al. A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. Am J Obstet Gynecol. 1981;141(5):547–55.

    CAS  PubMed  Google Scholar 

  118. Weiss NS, Szekely DR, English DR, et al. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA. 1979;242(3):261–4.

    CAS  PubMed  Google Scholar 

  119. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol. 1986;124(3):434–41.

    CAS  PubMed  Google Scholar 

  120. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol. 2000;53(4):385–91.

    CAS  PubMed  Google Scholar 

  121. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131–7.

    CAS  PubMed  Google Scholar 

  122. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer. 1989;59(3):445–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985;313(16):969–72. doi:10.1056/NEJM198510173131601.

    CAS  PubMed  Google Scholar 

  124. Lacey Jr JV, Brinton LA, Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomark Prev. 2005;14(7):1724–31. doi:10.1158/1055-9965.EPI-05-0111.

    CAS  Google Scholar 

  125. Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol. 2014;142:16–29. doi:10.1016/j.jsbmb.2013.10.011.

    CAS  PubMed  Google Scholar 

  126. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med. 1979;300(1):9–13. doi:10.1056/NEJM197901043000103.

    CAS  PubMed  Google Scholar 

  127. Gray Sr LA, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol. 1977;49(4):385–9.

    PubMed  Google Scholar 

  128. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298(6667):147–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology. 1993;4(1):20–4.

    CAS  PubMed  Google Scholar 

  130. Cushing KL, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol. 1998;91(1):35–9.

    CAS  PubMed  Google Scholar 

  131. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9. doi:10.1016/j.jsbmb.2013.05.001.

    CAS  PubMed  Google Scholar 

  132. Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. Am J Epidemiol. 1982;116(2):333–42.

    CAS  PubMed  Google Scholar 

  133. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–25.

    CAS  PubMed  Google Scholar 

  134. Karageorgi S, Hankinson SE, Kraft P, et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976-2004. Int J Cancer. 2010;126(1):208–16. doi:10.1002/ijc.24672.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 2013;132(2):417–26. doi:10.1002/ijc.27623.

    CAS  PubMed  Google Scholar 

  136. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol. 2007;197(2):139. doi:10.1016/j.ajog.2007.01.019.

    PubMed  Google Scholar 

  137. Lacey Jr JV, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer. 2007;109(7):1303–11. doi:10.1002/cncr.22525.

    CAS  PubMed  Google Scholar 

  138. Chang SC, Lacey Jr JV, Brinton LA, et al. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomark Prev. 2007;16(4):723–30. doi:10.1158/1055-9965.EPI-06-0675.

    CAS  Google Scholar 

  139. Beral V, Bull D, Reeves G, et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543–51. doi:10.1016/S0140-6736(05)66455-0.

    PubMed  Google Scholar 

  140. Shields TS, Weiss NS, Voigt LF, et al. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Epidemiology. 1999;10(6):733–8.

    CAS  PubMed  Google Scholar 

  141. Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol. 2010;172(12):1394–403. doi:10.1093/aje/kwq300.

    PubMed  Google Scholar 

  142. Phipps AI, Doherty JA, Voigt LF, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control. 2011;22(12):1639–46. doi:10.1007/s10552-011-9840-6.

    PubMed  PubMed Central  Google Scholar 

  143. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2007;18(4):399–413. doi:10.1007/s10552-006-0113-8.

    PubMed  Google Scholar 

  144. Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohort. Cancer Causes Control. 2010;21(9):1407–16. doi:10.1007/s10552-010-9568-8.

    PubMed  PubMed Central  Google Scholar 

  145. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomark Prev. 2008;17(1):73–9. doi:10.1158/1055-9965.EPI-07-2567.

    CAS  Google Scholar 

  146. Franks AL, Kendrick JS, Tyler Jr CW. Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am J Obstet Gynecol. 1987;156(1):20–3.

    CAS  PubMed  Google Scholar 

  147. Koumantaki Y, Tzonou A, Koumantakis E, et al. A case-control study of cancer of endometrium in Athens. Int J Cancer. 1989;43(5):795–9.

    CAS  PubMed  Google Scholar 

  148. Rubin GL, Peterson HB, Lee NC, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990;162(1):148–54.

    CAS  PubMed  Google Scholar 

  149. Weiss NS, Farewall VT, Szekely DR, et al. Oestrogens and endometrial cancer: effect of other risk factors on the association. Maturitas. 1980;2(3):185–90.

    CAS  PubMed  Google Scholar 

  150. Parazzini F, La Vecchia C, Negri E, et al. Smoking and risk of endometrial cancer: results from an Italian case-control study. Gynecol Oncol. 1995;56(2):195–9. doi:10.1006/gyno.1995.1031.

    CAS  PubMed  Google Scholar 

  151. Newcomer LM, Newcomb PA, Trentham-Dietz A, et al. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control. 2001;12(9):829–35.

    CAS  PubMed  Google Scholar 

  152. Jelovsek FR, Hammond CB, Woodard BH, et al. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol. 1980;137(1):85–91.

    CAS  PubMed  Google Scholar 

  153. Hoogerland DL, Buchler DA, Crowley JJ, et al. Estrogen use - risk of endometrial carcinoma. Gynecol Oncol. 1978;6(5):451–8.

    CAS  PubMed  Google Scholar 

  154. Schonfeld SJ, Hartge P, Pfeiffer RM, et al. An aggregated analysis of hormonal factors and endometrial cancer risk by parity. Cancer. 2013;119(7):1393–401. doi:10.1002/cncr.27909.

    PubMed  Google Scholar 

  155. Hulka BS, Chambless LE, Kaufman DG, et al. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA. 1982;247(4):475–7.

    CAS  PubMed  Google Scholar 

  156. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med. 1980;303(18):1045–7. doi:10.1056/NEJM198010303031807.

    CAS  PubMed  Google Scholar 

  157. Levi F, La Vecchia C, Gulie C, et al. Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control. 1991;2(2):99–103.

    CAS  PubMed  Google Scholar 

  158. Weiderpass E, Adami HO, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(4):277–84.

    CAS  PubMed  Google Scholar 

  159. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527–37.

    CAS  PubMed  Google Scholar 

  160. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995;87(9):645–51.

    CAS  PubMed  Google Scholar 

  161. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343(8895):448–52.

    PubMed  Google Scholar 

  162. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87(18):1359–64.

    CAS  PubMed  Google Scholar 

  163. Curtis RE, Boice Jr JD, Shriner DA, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996;88(12):832–4.

    CAS  PubMed  Google Scholar 

  164. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 1988;2(8610):563.

    CAS  PubMed  Google Scholar 

  165. Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol. 1995;59(2):186–90. doi:10.1006/gyno.1995.0005.

    CAS  PubMed  Google Scholar 

  166. Sasco AJ, Chaplain G, Amoros E, et al. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology. 1996;7(1):9–13.

    CAS  PubMed  Google Scholar 

  167. IARC. Some pharmaceutical drugs. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Lyon: IARC; 1996.

    Google Scholar 

  168. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–47.

    PubMed  PubMed Central  Google Scholar 

  169. Curtis RE, Freedman DM, Sherman ME, et al. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96(1):70–4.

    CAS  PubMed  Google Scholar 

  170. Bland AE, Calingaert B, Secord AA, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009;112(1):150–4. doi:10.1016/j.ygyno.2008.08.035.

    CAS  PubMed  Google Scholar 

  171. Henderson BE, Casagrande JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. Br J Cancer. 1983;47(6):749–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  172. Silverberg SG, Makowski EL, Roche WD. Endometrial carcinoma in women under 40 years of age: comparison of cases in oral contraceptive users and non-users. Cancer. 1977;39(2):592–8.

    CAS  PubMed  Google Scholar 

  173. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980;302(10):551–4. doi:10.1056/NEJM198003063021004.

    CAS  PubMed  Google Scholar 

  174. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum Reprod. 1997;12(9):1851–63.

    CAS  PubMed  Google Scholar 

  175. Voigt LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control. 1994;5(3):227–33.

    CAS  PubMed  Google Scholar 

  176. Felix AS, Gaudet MM, La Vecchia C, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2015;136(5):E410–22. doi:10.1002/ijc.29229.

    CAS  PubMed  Google Scholar 

  177. Beining RM, Dennis LK, Smith EM, et al. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol. 2008;18(6):492–9. doi:10.1016/j.annepidem.2007.11.011.

    PubMed  Google Scholar 

  178. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception. 2007;75(6 Suppl):S60–9. doi:10.1016/j.contraception.2007.01.002.

    PubMed  Google Scholar 

  179. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49(2):186–90

    Google Scholar 

  180. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 1983;249(21):2909–12.

    CAS  PubMed  Google Scholar 

  181. Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric. 2006;9(5):368–79.

    CAS  PubMed  Google Scholar 

  182. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9(3):e1001182. doi:10.1371/journal.pmed.1001182.

    PubMed  PubMed Central  Google Scholar 

  183. Lacey Jr JV, Brinton LA, Mortel R, et al. Tubal sterilization and risk of cancer of the endometrium. Gynecol Oncol. 2000;79(3):482–4. doi:10.1006/gyno.2000.5970.

    PubMed  Google Scholar 

  184. Rosenblatt K, Thomas D. Association between tubal ligation and endometrial cancer. Int J Cancer. 1997;71(1):129–30.

    CAS  PubMed  Google Scholar 

  185. Castellsague X, Thompson WD, Dubrow R. Tubal sterilization and the risk of endometrial cancer. Int J Cancer. 1996;65(5):607–12. doi:10.1002/(SICI)1097-0215(19960301)65:5<607::AID-IJC9>3.0.CO;2-6.

    CAS  PubMed  Google Scholar 

  186. Kjaer SK, Mellemkjaer L, Brinton LA, et al. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol. 2004;33(3):596–602. doi:10.1093/ije/dyh046.

    PubMed  Google Scholar 

  187. Zhang Y, Liu H, Yang S, et al. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29(1):e21–9. doi:10.5301/jbm.5000047.

    PubMed  Google Scholar 

  188. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.

    PubMed  Google Scholar 

  189. Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006.

    Google Scholar 

  190. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi:10.1136/bmj.39367.495995.AE.

    PubMed  PubMed Central  Google Scholar 

  191. Ward KK, Roncancio AM, Shah NR, et al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol. 2013;209(6):579. doi:10.1016/j.ajog.2013.08.007.

    PubMed  Google Scholar 

  192. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. Journal of the National Cancer Institute 2015;107(3) doi: 10.1093/jnci/dju428

  193. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer. 2000;7(2):73–83.

    CAS  PubMed  Google Scholar 

  194. Conroy MB, Sattelmair JR, Cook NR, et al. Physical activity, adiposity, and risk of endometrial cancer. Cancer Causes Control. 2009;20(7):1107–15. doi:10.1007/s10552-009-9313-3.

    PubMed  PubMed Central  Google Scholar 

  195. Dal Maso L, Tavani A, Zucchetto A, et al. Anthropometric measures at different ages and endometrial cancer risk. Br J Cancer. 2011;104(7):1207–13. doi:10.1038/bjc.2011.63.

    CAS  PubMed  Google Scholar 

  196. Folsom AR, Kaye SA, Potter JD, et al. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women’s Health Study. Cancer Res. 1989;49(23):6828–31.

    CAS  PubMed  Google Scholar 

  197. Goodman MT, Hankin JH, Wilkens LR, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res. 1997;57(22):5077–85.

    CAS  PubMed  Google Scholar 

  198. Reeves KW, Carter GC, Rodabough RJ, et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women’s Health Initiative. Gynecol Oncol. 2011;121(2):376–82. doi:10.1016/j.ygyno.2011.01.027.

    PubMed  PubMed Central  Google Scholar 

  199. Swanson CA, Potischman N, Wilbanks GD, et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomark Prev. 1993;2(4):321–7.

    CAS  Google Scholar 

  200. Xu WH, Matthews CE, Xiang YB, et al. Effect of adiposity and fat distribution on endometrial cancer risk in Shanghai women. Am J Epidemiol. 2005;161(10):939–47. doi:10.1093/aje/kwi127.

    PubMed  Google Scholar 

  201. Key TJ, Allen NE, Verkasalo PK, et al. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc. 2001;60(1):81–9.

    CAS  PubMed  Google Scholar 

  202. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;120(12):2656–64. doi:10.1002/ijc.22578.

    CAS  PubMed  Google Scholar 

  203. Moore SC, Gierach GL, Schatzkin A, et al. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103(7):933–8. doi:10.1038/sj.bjc.6605902.

    CAS  PubMed  PubMed Central  Google Scholar 

  204. Voskuil DW, Monninkhof EM, Elias SG, et al. Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomark Prev. 2007;16(4):639–48. doi:10.1158/1055-9965.EPI-06-0742.

    Google Scholar 

  205. Cust AE, Armstrong BK, Friedenreich CM, et al. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control. 2007;18(3):243–58. doi:10.1007/s10552-006-0094-7.

    PubMed  Google Scholar 

  206. Keum N, Ju W, Lee DH, et al. Leisure-time physical activity and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer. 2014;135(3):682–94. doi:10.1002/ijc.28687.

    CAS  PubMed  Google Scholar 

  207. Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation to cancer risk: a meta-analysis. Journal of the National Cancer Institute 2014;106(7) doi:10.1093/jnci/dju098.

  208. IARC. IARC handbooks on cancer prevention: weight control and physical activity. Lyon: IARC Press; 2002.

    Google Scholar 

  209. McTiernan A, Tworoger SS, Ulrich CM, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res. 2004;64(8):2923–8.

    CAS  PubMed  Google Scholar 

  210. Liao C, Zhang D, Mungo C, et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135(1):163–71. doi:10.1016/j.ygyno.2014.07.095.

    PubMed  PubMed Central  Google Scholar 

  211. Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74. doi:10.1007/s00125-007-0681-5.

    CAS  PubMed  Google Scholar 

  212. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013;23(2):294–303. doi:10.1097/IGC.0b013e31827b8430.

    PubMed  Google Scholar 

  213. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomark Prev. 2007;16(2):276–80. doi:10.1158/1055-9965.EPI-06-0751.

    Google Scholar 

  214. Anderson KE, Anderson E, Mink PJ, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomark Prev. 2001;10(6):611–6.

    CAS  Google Scholar 

  215. Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG, et al. Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control. 2000;11(8):707–11.

    CAS  PubMed  Google Scholar 

  216. Bjorge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol. 2010;171(8):892–902. doi:10.1093/aje/kwq006.

    PubMed  Google Scholar 

  217. Becker C, Jick SS, Meier CR, et al. Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol. 2013;129(3):565–9. doi:10.1016/j.ygyno.2013.03.009.

    CAS  PubMed  Google Scholar 

  218. Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432–9. doi:10.1038/bjc.2014.407.

    CAS  PubMed  PubMed Central  Google Scholar 

  219. Ko EM, Sturmer T, Hong JL, et al. Metformin and the risk of endometrial cancer: a population-based cohort study. Gynecol Oncol. 2015;136(2):341–7. doi:10.1016/j.ygyno.2014.12.001.

    CAS  PubMed  Google Scholar 

  220. Trabert B, Wentzensen N, Felix AS, et al. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. Cancer Epidemiol Biomark Prev. 2015;24(1):261–7. doi:10.1158/1055-9965.EPI-14-0923.

    Google Scholar 

  221. Cust AE, Kaaks R, Friedenreich C, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007;14(3):755–67. doi:10.1677/ERC-07-0132.

    CAS  PubMed  Google Scholar 

  222. Friedenreich CM, Biel RK, Lau DC, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev. 2011;20(11):2384–95. doi:10.1158/1055-9965.EPI-11-0715.

    CAS  Google Scholar 

  223. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22(4):884–9. doi:10.1093/annonc/mdq464.

    CAS  PubMed  Google Scholar 

  224. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293–7. doi:10.1016/j.ejca.2007.11.005.

    PubMed  Google Scholar 

  225. Zhang Y, Liu Z, Yu X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol. 2010;117(1):41–6. doi:10.1016/j.ygyno.2009.12.029.

    CAS  PubMed  Google Scholar 

  226. Shu XO, Brinton LA, Zheng W, et al. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer. 1991;49(1):38–43.

    CAS  PubMed  Google Scholar 

  227. Elwood JM, Cole P, Rothman KJ, et al. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977;59(4):1055–60.

    CAS  PubMed  Google Scholar 

  228. Ewertz M, Schou G, Boice Jr JD. The joint effect of risk factors on endometrial cancer. Eur J Cancer Clin Oncol. 1988;24(2):189–94.

    CAS  PubMed  Google Scholar 

  229. Kalandidi A, Tzonou A, Lipworth L, et al. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology. 1996;53(5):354–9.

    CAS  PubMed  Google Scholar 

  230. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res. 1988;48(21):6217–21.

    CAS  PubMed  Google Scholar 

  231. McPherson CP, Sellers TA, Potter JD, et al. Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol. 1996;143(12):1195–202.

    CAS  PubMed  Google Scholar 

  232. Petridou E, Koukoulomatis P, Dessypris N, et al. Why is endometrial cancer less common in Greece than in other European Union countries? Eur J Cancer Prev. 2002;11(5):427–32.

    CAS  PubMed  Google Scholar 

  233. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127(2):442–51. doi:10.1002/ijc.25050.

    CAS  PubMed  Google Scholar 

  234. Fujita M, Tase T, Kakugawa Y, et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. Tohoku J Exp Med. 2008;216(4):297–307.

    PubMed  Google Scholar 

  235. Reis N, Beji NK. Risk factors for endometrial cancer in Turkish women: results from a hospital-based case-control study. Eur J Oncol Nurs. 2009;13(2):122–7. doi:10.1016/j.ejon.2009.01.007.

    PubMed  Google Scholar 

  236. Zucchetto A, Serraino D, Polesel J, et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009;18(4):316–21.

    PubMed  Google Scholar 

  237. Niwa K, Imai A, Hashimoto M, et al. A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol Rep. 2000;7(1):89–93.

    CAS  PubMed  Google Scholar 

  238. Hirose K, Tajima K, Hamajima N, et al. Subsite (cervix/endometrium)-specific risk and protective factors in uterus cancer. Jpn J Cancer Res. 1996;87(9):1001–9.

    CAS  PubMed  Google Scholar 

  239. Pettersson B, Adami HO, Bergstrom R, et al. Menstruation span--a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand. 1986;65(3):247–55.

    CAS  PubMed  Google Scholar 

  240. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res. 1999;59(15):3658–62.

    CAS  PubMed  Google Scholar 

  241. Spengler RF, Clarke EA, Woolever CA, et al. Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases. Am J Epidemiol. 1981;114(4):497–506.

    CAS  PubMed  Google Scholar 

  242. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer. 1966;19(4):489–520.

    CAS  PubMed  Google Scholar 

  243. Xu WH, Xiang YB, Ruan ZX, et al. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int J Cancer. 2004;108(4):613–9. doi:10.1002/ijc.11598.

    CAS  PubMed  Google Scholar 

  244. Albrektsen G, Heuch I, Tretli S, et al. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer. 1995;61(4):485–90.

    CAS  PubMed  Google Scholar 

  245. Albrektsen G, Heuch I, Wik E, et al. Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer. 2009;19(4):665–9. doi:10.1111/IGC.0b013e3181a3e1bf.

    PubMed  Google Scholar 

  246. Hemminki K, Bermejo JL, Granstrom C. Endometrial cancer: population attributable risks from reproductive, familial and socioeconomic factors. Eur J Cancer. 2005;41(14):2155–9. doi:10.1016/j.ejca.2005.03.031.

    PubMed  Google Scholar 

  247. Mogren I, Stenlund H, Hogberg U. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta Oncol. 2001;40(7):849–54.

    CAS  PubMed  Google Scholar 

  248. Neale RE, Darlington S, Murphy MF, et al. The effects of twins, parity and age at first birth on cancer risk in Swedish women. Twin Res Hum Genet. 2005;8(2):156–62. doi:10.1375/1832427053738809.

    PubMed  Google Scholar 

  249. Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer. 1998;76(6):784–6.

    CAS  PubMed  Google Scholar 

  250. Pfeiffer RM, Mitani A, Landgren O, et al. Timing of births and endometrial cancer risk in Swedish women. Cancer Causes Control. 2009;20(8):1441–9. doi:10.1007/s10552-009-9370-7.

    PubMed  PubMed Central  Google Scholar 

  251. Wernli KJ, Ray RM, Gao DL, et al. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control. 2006;17(7):949–55. doi:10.1007/s10552-006-0034-6.

    PubMed  Google Scholar 

  252. Epplein M, Reed SD, Voigt LF, et al. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol. 2008;168(6):563–70. doi:10.1093/aje/kwn168. discussion 71–6.

    PubMed  PubMed Central  Google Scholar 

  253. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, et al. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev. 1996;5(2):105–12.

    CAS  PubMed  Google Scholar 

  254. Inoue M, Okayama A, Fujita M, et al. A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res. 1994;85(4):346–50.

    CAS  PubMed  Google Scholar 

  255. Lambe M, Wuu J, Weiderpass E, et al. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(1):43–9.

    CAS  PubMed  Google Scholar 

  256. Parslov M, Lidegaard O, Klintorp S, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol. 2000;182(1 Pt 1):23–9.

    CAS  PubMed  Google Scholar 

  257. Terry P, Baron JA, Weiderpass E, et al. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer. 1999;82(1):38–42.

    CAS  PubMed  Google Scholar 

  258. Hinkula M, Pukkala E, Kyyronen P, et al. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer. 2002;98(6):912–5.

    CAS  PubMed  Google Scholar 

  259. Kvale G, Heuch I, Nilssen S. Reproductive factors and cancers of the breast and genital organs--are the different cancer sites similarly affected? Cancer Detect Prev. 1991;15(5):369–77.

    CAS  PubMed  Google Scholar 

  260. Brinton LA, Sakoda LC, Lissowska J, et al. Reproductive risk factors for endometrial cancer among Polish women. Br J Cancer. 2007;96(9):1450–6. doi:10.1038/sj.bjc.6603731.

    CAS  PubMed  PubMed Central  Google Scholar 

  261. Lesko SM, Rosenberg L, Kaufman DW, et al. Endometrial cancer and age at last delivery: evidence for an association. Am J Epidemiol. 1991;133(6):554–9.

    CAS  PubMed  Google Scholar 

  262. La Vecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984;73(3):667–71.

    PubMed  Google Scholar 

  263. Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012;176(4):269–78. doi:10.1093/aje/kws129.

    PubMed  PubMed Central  Google Scholar 

  264. Newcomb PA, Trentham-Dietz A. Breast feeding practices in relation to endometrial cancer risk, USA. Cancer Causes Control. 2000;11(7):663–7.

    CAS  PubMed  Google Scholar 

  265. Sugawara Y, Kakizaki M, Nagai M, et al. Lactation pattern and the risk for hormone-related female cancer in Japan: the Ohsaki Cohort Study. Eur J Cancer Prev. 2013;22(2):187–92. doi:10.1097/CEJ.0b013e3283564610.

    PubMed  Google Scholar 

  266. Okamura C, Tsubono Y, Ito K, et al. Lactation and risk of endometrial cancer in Japan: a case-control study. Tohoku J Exp Med. 2006;208(2):109–15.

    PubMed  Google Scholar 

  267. Rosenblatt KA, Thomas DB. Prolonged lactation and endometrial cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1995;24(3):499–503.

    CAS  PubMed  Google Scholar 

  268. Yang HP, Cook LS, Weiderpass E, et al. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Br J Cancer. 2015;112(5):925–33. doi:10.1038/bjc.2015.24.

    CAS  PubMed  PubMed Central  Google Scholar 

  269. Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best practice & research. Clinical endocrinology & metabolism. 2006;20(2):235–44. doi:10.1016/j.beem.2006.03.005.

    CAS  Google Scholar 

  270. Speert H. Carcinoma of the endometrium in young women. Surgery, gynecology & obstetrics. 1949;88(3):332–6.

    CAS  Google Scholar 

  271. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58. doi:10.1093/humupd/dmu012.

    PubMed  PubMed Central  Google Scholar 

  272. Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121(6):501–08 e3. doi:10.1016/j.amjmed.2008.01.044.

    CAS  PubMed  Google Scholar 

  273. Bradlow HL, Telang NT, Sepkovic DW, et al. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996;150(Suppl):S259–65.

    CAS  PubMed  Google Scholar 

  274. Michnovicz JJ, Hershcopf RJ, Naganuma H, et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986;315(21):1305–9. doi:10.1056/NEJM198611203152101.

    CAS  PubMed  Google Scholar 

  275. Zhou Y, Jorgensen EM, Gan Y, et al. Cigarette smoke increases progesterone receptor and homeobox A10 expression in human endometrium and endometrial cells: a potential role in the decreased prevalence of endometrial pathology in smokers. Biol Reprod. 2011;84(6):1242–7. doi:10.1095/biolreprod.110.087494.

    CAS  PubMed  PubMed Central  Google Scholar 

  276. Friedman AJ, Ravnikar VA, Barbieri RL. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril. 1987;47(3):398–401.

    CAS  PubMed  Google Scholar 

  277. Key TJ, Pike MC, Baron JA, et al. Cigarette smoking and steroid hormones in women. J Steroid Biochem Mol Biol. 1991;39(4A):529–34.

    CAS  PubMed  Google Scholar 

  278. Key TJ, Pike MC, Brown JB, et al. Cigarette smoking and urinary oestrogen excretion in premenopausal and post-menopausal women. Br J Cancer. 1996;74(8):1313–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  279. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(1):89–98. doi:10.1097/AOG.0000000000000563.

    PubMed  Google Scholar 

  280. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomark Prev. 1996;5(6):411–7.

    CAS  Google Scholar 

  281. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.

    PubMed  PubMed Central  Google Scholar 

  282. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18. doi:10.1111/j.1399-0004.2009.01230.x.

    CAS  PubMed  PubMed Central  Google Scholar 

  283. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6(1):105–10.

    CAS  PubMed  Google Scholar 

  284. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.

    CAS  PubMed  Google Scholar 

  285. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136–44. doi:10.1038/ng.2503.

    CAS  PubMed  Google Scholar 

  286. Church JM. Polymerase proofreading-associated polyposis: a new, dominantly inherited syndrome of hereditary colorectal cancer predisposition. Dis Colon Rectum. 2014;57(3):396–7. doi:10.1097/DCR.0000000000000084.

    PubMed  Google Scholar 

  287. Meyer LA, Westin SN, Lu KH, et al. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther. 2008;8(7):1159–67. doi:10.1586/14737140.8.7.1159.

    CAS  PubMed  Google Scholar 

  288. Gaudet MM, Lacey Jr JV, Lissowska J, et al. Genetic variation in CYP17 and endometrial cancer risk. Hum Genet. 2008;123(2):155–62. doi:10.1007/s00439-007-0454-8.

    CAS  PubMed  Google Scholar 

  289. Olson SH, Orlow I, Bayuga S, et al. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control. 2008;19(9):955–63. doi:10.1007/s10552-008-9160-7.

    PubMed  PubMed Central  Google Scholar 

  290. O'Mara TA, Fahey P, Ferguson K, et al. Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis. 2011;32(3):331–5. doi:10.1093/carcin/bgq263.

    PubMed  Google Scholar 

  291. Setiawan VW, Doherty JA, Shu XO, et al. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomark Prev. 2009;18(1):242–7. doi:10.1158/1055-9965.EPI-08-0689.

    CAS  Google Scholar 

  292. Setiawan VW, Hankinson SE, Colditz GA, et al. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomark Prev. 2004;13(2):213–9.

    CAS  Google Scholar 

  293. Weiderpass E, Persson I, Melhus H, et al. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 2000;21(4):623–7.

    CAS  PubMed  Google Scholar 

  294. Yang HP, Garcia-Closas M, Lacey Jr JV, et al. Genetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2009;18(2):585–9. doi:10.1158/1055-9965.EPI-08-0677.

    CAS  Google Scholar 

  295. Yang HP, Gonzalez Bosquet J, Li Q, et al. Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis. 2010;31(5):827–33. doi:10.1093/carcin/bgp328.

    CAS  PubMed  PubMed Central  Google Scholar 

  296. Delahanty RJ, Beeghly-Fadiel A, Xiang YB, et al. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol. 2011;174(10):1115–26. doi:10.1093/aje/kwr233.

    PubMed  PubMed Central  Google Scholar 

  297. Gaudet MM, Yang HP, Bosquet JG, et al. No association between FTO or HHEX and endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2010;19(8):2106–9. doi:10.1158/1055-9965.EPI-10-0515.

    CAS  Google Scholar 

  298. Lurie G, Gaudet MM, Spurdle AB, et al. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011;6(2):e16756. doi:10.1371/journal.pone.0016756.

    CAS  PubMed  PubMed Central  Google Scholar 

  299. Spurdle AB, Thompson DJ, Ahmed S, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43(5):451–4. doi:10.1038/ng.812.

    CAS  PubMed  PubMed Central  Google Scholar 

  300. Long J, Zheng W, Xiang YB, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomark Prev. 2012;21(6):980–7. doi:10.1158/1055-9965.EPI-11-1160.

    CAS  Google Scholar 

  301. De Vivo I, Prescott J, Setiawan VW, et al. Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014;133(2):211–24. doi:10.1007/s00439-013-1369-1.

    PubMed  Google Scholar 

  302. Setiawan VW, Haessler J, Schumacher F, et al. HNF1B and endometrial cancer risk: results from the PAGE study. PLoS One. 2012;7(1):e30390. doi:10.1371/journal.pone.0030390.

    CAS  PubMed  PubMed Central  Google Scholar 

  303. Chen MM, Crous-Bou M, Setiawan VW, et al. Exome-wide association study of endometrial cancer in a multiethnic population. PLoS One. 2014;9(5):e97045. doi:10.1371/journal.pone.0097045.

    PubMed  PubMed Central  Google Scholar 

  304. Yang HP, Gierach GL, Danforth KN, et al. Alcohol and endometrial cancer risk in the NIH-AARP diet and health study. Int J Cancer. 2011;128(12):2953–61. doi:10.1002/ijc.25623.

    CAS  PubMed  Google Scholar 

  305. Neill AS, Nagle CM, Protani MM, et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146–55. doi:10.1002/ijc.27717.

    CAS  PubMed  Google Scholar 

  306. Rowlands IJ, Nagle CM, Spurdle AB, et al. Gynecological conditions and the risk of endometrial cancer. Gynecol Oncol. 2011;123(3):537–41. doi:10.1016/j.ygyno.2011.08.022.

    PubMed  Google Scholar 

  307. DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26(25):4151–9. doi:10.1200/JCO.2007.14.0921.

    PubMed  PubMed Central  Google Scholar 

  308. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. 2007.

    Google Scholar 

  309. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol. 1997;10(10):963–8.

    CAS  PubMed  Google Scholar 

  310. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851–6. doi:10.1007/s10552-010-9612-8.

    PubMed  PubMed Central  Google Scholar 

  311. Yang HP, Wentzensen N, Trabert B, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol. 2013;177(2):142–51. doi:10.1093/aje/kws200.

    PubMed  Google Scholar 

  312. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18. doi:10.1200/JCO.2012.48.2596.

    PubMed  PubMed Central  Google Scholar 

  313. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev. 2009;18(10):2569–78. doi:10.1158/1055-9965.EPI-09-0372.

    Google Scholar 

  314. Ito K, Suzuki T, Akahira J, et al. Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int J Cancer. 2002;99(5):652–7. doi:10.1002/ijc.10394.

    CAS  PubMed  Google Scholar 

  315. Gibson DA, Simitsidellis I, Collins F, et al. Evidence of androgen action in endometrial and ovarian cancers. Endocrine-related cancer. 2014;21(4):T203–18. doi:10.1530/ERC-13-0551.

    CAS  PubMed  Google Scholar 

  316. Nantermet PV, Masarachia P, Gentile MA, et al. Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology. 2005;146(2):564–78. doi:10.1210/en.2004-1132.

    CAS  PubMed  Google Scholar 

  317. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88(16):1127–35.

    CAS  PubMed  Google Scholar 

  318. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.

    CAS  PubMed  Google Scholar 

  319. Bishop EA, Lightfoot S, Thavathiru E, et al. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Investig. 2014;32(3):63–70. doi:10.3109/07357907.2013.877479.

    CAS  Google Scholar 

  320. Irwin JC, de las Fuentes L, Dsupin BA, et al. Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion. Regul Pept. 1993;48(1-2):165–77.

    CAS  PubMed  Google Scholar 

  321. Lee PD, Giudice LC, Conover CA, et al. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med. 1997;216(3):319–57.

    CAS  PubMed  Google Scholar 

  322. Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518–25. doi:10.1016/j.ajog.2011.05.042.

    PubMed  PubMed Central  Google Scholar 

  323. Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of inflammatory markers and the risk of endometrial cancer. Eur J Cancer Prev. 2013;22(4):374–9. doi:10.1097/CEJ.0b013e32835b3813.

    CAS  PubMed  Google Scholar 

  324. Weiderpass E, Brismar K, Bellocco R, et al. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer. 2003;89(9):1697–704. doi:10.1038/sj.bjc.6601312.

    CAS  PubMed  PubMed Central  Google Scholar 

  325. Zhan Y, Wang J, Ma Y, et al. Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. Int J Cancer. 2013;132(2):411–6. doi:10.1002/ijc.27622.

    CAS  PubMed  Google Scholar 

  326. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004;108(2):262–8. doi:10.1002/ijc.11544.

    CAS  PubMed  Google Scholar 

  327. Troisi R, Potischman N, Hoover RN, et al. Insulin and endometrial cancer. Am J Epidemiol. 1997;146(6):476–82.

    CAS  PubMed  Google Scholar 

  328. Augustin LS, Dal Maso L, Franceschi S, et al. Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology. 2004;67(1):54–9. doi:10.1159/000080286.

    CAS  PubMed  Google Scholar 

  329. Lacey Jr JV, Potischman N, Madigan MP, et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomark Prev. 2004;13(4):607–12.

    CAS  Google Scholar 

  330. Oh JC, Wu W, Tortolero-Luna G, et al. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2004;13(5):748–52.

    CAS  Google Scholar 

  331. Petridou E, Koukoulomatis P, Alexe DM, et al. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology. 2003;64(4):341–5.

    PubMed  Google Scholar 

  332. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab. 2007;92(1):255–63. doi:10.1210/jc.2006-1371.

    CAS  PubMed  Google Scholar 

  333. Modugno F, Ness RB, Chen C, et al. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomark Prev. 2005;14(12):2840–7. doi:10.1158/1055-9965.EPI-05-0493.

    CAS  Google Scholar 

  334. Dossus L, Rinaldi S, Becker S, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocrine-related cancer. 2010;17(4):1007–19. doi:10.1677/ERC-10-0053.

    PubMed  PubMed Central  Google Scholar 

  335. Wang T, Rohan TE, Gunter MJ, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomark Prev. 2011;20(5):971–7. doi:10.1158/1055-9965.EPI-10-1222.

    CAS  Google Scholar 

  336. Dossus L, Lukanova A, Rinaldi S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis. Am J Epidemiol. 2013;177(8):787–99. doi:10.1093/aje/kws309.

    PubMed  Google Scholar 

  337. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88(3):993–7. doi:10.1210/jc.2002-021209.

    CAS  PubMed  Google Scholar 

  338. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004;89(3):1160–3. doi:10.1210/jc.2003-031716.

    CAS  PubMed  Google Scholar 

  339. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–81. doi:10.1002/cncr.21866.

    CAS  PubMed  Google Scholar 

  340. Ashizawa N, Yahata T, Quan J, et al. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010;119(1):65–9. doi:10.1016/j.ygyno.2010.07.007.

    CAS  PubMed  Google Scholar 

  341. Luhn P, Dallal CM, Weiss JM, et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev. 2013;22(7):1304–12. doi:10.1158/1055-9965.EPI-13-0258.

    CAS  Google Scholar 

  342. Dallal CM, Brinton LA, Bauer DC, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B ~ FIT cohort. Endocrine-related cancer. 2013;20(1):151–60. doi:10.1530/ERC-12-0229.

    CAS  PubMed  PubMed Central  Google Scholar 

  343. Soliman PT, Cui X, Zhang Q, et al. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses’ Health Study. Am J Obstet Gynecol. 2011;204(2):167 e1–5. doi:10.1016/j.ajog.2010.08.045.

    Google Scholar 

  344. Petridou E, Belechri M, Dessypris N, et al. Leptin and body mass index in relation to endometrial cancer risk. Annals of nutrition & metabolism. 2002;46(3-4):147–51.

    CAS  Google Scholar 

  345. Gaudet MM, Falk RT, Stevens RD, et al. Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study. J Clin Endocrinol Metab. 2012;97(9):3216–23. doi:10.1210/jc.2012-1490.

    CAS  PubMed  PubMed Central  Google Scholar 

  346. Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492. doi:10.1371/journal.pmed.1001492.

    PubMed  PubMed Central  Google Scholar 

  347. Hawkes AL, Quinn M, Gebski V, et al. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device +/- metformin +/- weight loss in endometrial cancer (feMME) trial. Contemporary clinical trials. 2014;39(1):14–21. doi:10.1016/j.cct.2014.06.014.

    CAS  PubMed  Google Scholar 

  348. Bakkum-Gamez JN, Wentzensen N, Maurer MJ, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015. doi:10.1016/j.ygyno.2015.01.552.

    Google Scholar 

  349. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167. doi:10.1126/scitranslmed.3004952.

    Google Scholar 

  350. Fiegl H, Gattringer C, Widschwendter A, et al. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomark Prev. 2004;13(5):882–8.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Bethesda, MD, 20892, USA

    Ashley S. Felix Ph.D., M.P.H., Hannah P. Yang Ph.D., Sc.M. & Mark E. Sherman M.D.

  2. Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bethesda, MD, 20892, USA

    Daphne W. Bell Ph.D.

Authors
  1. Ashley S. Felix Ph.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah P. Yang Ph.D., Sc.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daphne W. Bell Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark E. Sherman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Sherman M.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA

    Lora Hedrick Ellenson

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Felix, A.S., Yang, H.P., Bell, D.W., Sherman, M.E. (2017). Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. In: Hedrick Ellenson, L. (eds) Molecular Genetics of Endometrial Carcinoma. Advances in Experimental Medicine and Biology, vol 943. Springer, Cham. https://doi.org/10.1007/978-3-319-43139-0_1

Download citation

Publish with us

Policies and ethics

Search

Navigation